"Ultimately, high-quality evidence to guide regulatory and policy decision-making must come from adequately designed (and funded) RCTs [randomized controlled trials]–the highest attainable standard of medical evidence, which we owe to patients affected by drug-resistant tuberculosis to strive for and maintain."
An editorial, authored by Lorenzo Guglielmetti, Marcus Low and Lindsay McKenna, published in Expert Review of Anti-infective Therapy.
To access the editorial, click here.